Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share (KYTX)
CUSIP: 501976104
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, par value $0.00001 per share
- Shares outstanding
- 56,833,213
- Total 13F shares
- 23,200,134
- Share change
- -2,558,806
- Total reported value
- $71,227,727
- Put/Call ratio
- 0%
- Price per share
- $3.07
- Number of holders
- 77
- Value change
- -$5,373,744
- Number of buys
- 44
- Number of sells
- 47
Quarterly Holders Quick Answers
What is CUSIP 501976104?
CUSIP 501976104 identifies KYTX - Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 501976104:
Top shareholders of KYTX - Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Fred E. Cohen |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
4,605,909
mixed-class rows
|
$9,580,576 | — | 29 May 2025 | |
| Vida Ventures Advisors, LLC |
13F
|
Company |
8%
|
4,523,924
|
$8,731,173 | — | 31 Mar 2025 | |
| GILEAD SCIENCES, INC. |
13F
3/4/5
|
Company · 10%+ Owner |
7.3%
|
4,126,119
|
$7,963,410 | — | 31 Mar 2025 | |
| Bain Capital Life Sciences Investors, LLC |
13F
3/4/5
|
Company · 10%+ Owner |
5.9%
|
3,368,370
|
$6,500,954 | — | 31 Mar 2025 | |
| Novo Holdings A/S |
13F
|
Company |
3.3%
|
1,850,000
|
$3,570,500 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
2.9%
|
1,676,268
|
$3,235,198 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
2.3%
|
1,298,449
|
$2,506,007 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.7%
|
993,620
|
$1,917,687 | — | 31 Mar 2025 | |
| Insight Holdings Group, LLC |
13F
|
Company |
1.7%
|
989,054
|
$1,908,874 | — | 31 Mar 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
1.2%
|
692,028
|
$1,335,614 | — | 31 Mar 2025 | |
| MBB PUBLIC MARKETS I LLC |
13F
|
Company |
1.1%
|
614,477
|
$1,185,941 | — | 31 Mar 2025 | |
| Catalio Capital Management, LP |
13F
|
Company |
1%
|
586,909
|
$1,132,734 | — | 31 Mar 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
1%
|
579,604
|
$1,120,000 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.99%
|
563,974
|
$1,088,604 | — | 31 Mar 2025 | |
| Peapod Lane Capital LLC |
13F
|
Company |
0.7%
|
396,221
|
$764,707 | — | 31 Mar 2025 | |
| Kera Capital Partners, Inc. |
13F
|
Company |
0.66%
|
376,186
|
$726,039 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.66%
|
374,578
|
$722,936 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.42%
|
238,239
|
$459,801 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.34%
|
191,664
|
$369,911 | — | 31 Mar 2025 | |
| SUPERSTRING CAPITAL MANAGEMENT LP |
13F
|
Company |
0.34%
|
191,287
|
$369,184 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.31%
|
177,670
|
$342,903 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.29%
|
165,370
|
$319,164 | — | 31 Mar 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.24%
|
136,300
|
$263,059 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.24%
|
134,910
|
$260,376 | — | 31 Mar 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.22%
|
124,958
|
$241,169 | — | 31 Mar 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.22%
|
122,977
|
$237,346 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.18%
|
104,460
|
$201,608 | — | 31 Mar 2025 | |
| Deutsche Girozentrale DekaBank |
13F
|
Individual |
0.01%
|
7,500
|
$181,000 | — | 31 Mar 2025 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
0.16%
|
90,242
|
$174,167 | — | 31 Mar 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.14%
|
81,390
|
$157,083 | — | 31 Mar 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.14%
|
80,900
|
$156,137 | — | 31 Mar 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.13%
|
71,057
|
$137,140 | — | 31 Mar 2025 | |
| Cubist Systematic Strategies, LLC |
13F
|
Company |
0.12%
|
68,628
|
$132,452 | — | 31 Mar 2025 | |
| PRELUDE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.12%
|
67,546
|
$130,364 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.09%
|
48,784
|
$94,153 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.08%
|
47,508
|
$91,691 | — | 31 Mar 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.08%
|
46,381
|
$89,515 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.07%
|
39,502
|
$76,239 | — | 31 Mar 2025 | |
| STIFEL FINANCIAL CORP |
13F
|
Company |
0.07%
|
39,163
|
$75,585 | — | 31 Mar 2025 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE |
13F
|
Company |
0.07%
|
38,602
|
$74,502 | — | 31 Mar 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.07%
|
37,828
|
$73,008 | — | 31 Mar 2025 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.06%
|
36,000
|
$69,480 | — | 31 Mar 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.06%
|
34,453
|
$66,494 | — | 31 Mar 2025 | |
| ALPS ADVISORS INC |
13F
|
Company |
0.06%
|
32,126
|
$62,003 | — | 31 Mar 2025 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.06%
|
31,614
|
$61,006 | — | 31 Mar 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.05%
|
30,010
|
$57,919 | — | 31 Mar 2025 | |
| SEI INVESTMENTS CO |
13F
|
Company |
0.04%
|
24,660
|
$47,594 | — | 31 Mar 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.04%
|
24,561
|
$47,403 | — | 31 Mar 2025 | |
| CAXTON CORP |
13F
|
Company |
0.04%
|
22,981
|
$44,354 | — | 31 Mar 2025 | |
| INTECH INVESTMENT MANAGEMENT LLC |
13F
|
Company |
0.04%
|
21,945
|
$42,354 | — | 31 Mar 2025 |
Institutional Holders of Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share (KYTX) as of Q2 2025
As of 30 Jun 2025,
Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share (KYTX) was held by
77 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
23,200,134 shares.
The largest 10 holders included
Vida Ventures Advisors, LLC, GILEAD SCIENCES, INC., Bain Capital Life Sciences Investors, LLC, PRICE T ROWE ASSOCIATES INC /MD/, VANGUARD GROUP INC, Insight Holdings Group, LLC, FRANKLIN RESOURCES INC, MBB PUBLIC MARKETS I LLC, Catalio Capital Management, LP, and BlackRock, Inc..
This page lists
77
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
86
Q2 2025 holders
77
Holder diff
-9
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.